C4 Therapeutics, Inc. (NASDAQ:CCCC – Free Report) – Brookline Capital Markets boosted their FY2026 earnings per share estimates for C4 Therapeutics in a research note issued on Thursday, November 5th. Brookline Capital Markets analyst L. Cann now expects that the company will earn ($0.69) per share for the year, up from their previous estimate of ($0.80). The consensus estimate for C4 Therapeutics’ current full-year earnings is ($0.81) per share. Brookline Capital Markets also issued estimates for C4 Therapeutics’ Q4 2026 earnings at ($0.15) EPS, FY2027 earnings at ($0.89) EPS and FY2028 earnings at ($1.57) EPS.
C4 Therapeutics (NASDAQ:CCCC – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.03. C4 Therapeutics had a negative return on equity of 45.45% and a negative net margin of 289.44%. The company had revenue of $8.47 million during the quarter, compared to analysts’ expectations of $8.52 million.
A number of other analysts also recently issued reports on the company. JPMorgan Chase & Co. assumed coverage on C4 Therapeutics in a research report on Friday, October 9th. They set an “overweight” rating and a $10.00 price objective for the company. Lake Street Capital began coverage on shares of C4 Therapeutics in a report on Wednesday, October 28th. They issued a “buy” rating and a $11.00 price objective on the stock. Wall Street Zen cut shares of C4 Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Evercore lowered shares of C4 Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 2nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of C4 Therapeutics in a research note on Thursday, October 15th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $8.50.
Get Our Latest Analysis on C4 Therapeutics
C4 Therapeutics Stock Up 1.6%
Shares of C4 Therapeutics stock opened at $3.15 on Tuesday. C4 Therapeutics has a 52 week low of $1.69 and a 52 week high of $5.17. The business’s fifty day simple moving average is $3.21 and its 200-day simple moving average is $3.23. The firm has a market cap of $387.54 million, a PE ratio of -4.37 and a beta of 3.16.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of CCCC. Wasatch Advisors LP grew its stake in shares of C4 Therapeutics by 18.9% in the second quarter. Wasatch Advisors LP now owns 3,522,644 shares of the company’s stock valued at $16,451,000 after buying an additional 560,883 shares in the last quarter. Candriam S.C.A. lifted its stake in C4 Therapeutics by 53.6% during the 3rd quarter. Candriam S.C.A. now owns 2,760,346 shares of the company’s stock worth $9,226,000 after acquiring an additional 963,409 shares in the last quarter. Renaissance Technologies LLC lifted its stake in C4 Therapeutics by 53.6% during the 1st quarter. Renaissance Technologies LLC now owns 2,461,815 shares of the company’s stock worth $6,475,000 after acquiring an additional 859,235 shares in the last quarter. Congress Asset Management Co. lifted its stake in C4 Therapeutics by 25.2% during the 3rd quarter. Congress Asset Management Co. now owns 1,256,692 shares of the company’s stock worth $4,185,000 after acquiring an additional 253,255 shares in the last quarter. Finally, Velan Capital Investment Management LP purchased a new position in C4 Therapeutics during the 2nd quarter valued at about $2,662,000. 78.81% of the stock is currently owned by hedge funds and other institutional investors.
C4 Therapeutics Company Profile
C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary TORPEDO platform to design targeted protein degraders, which are intended to direct specific proteins to the cell’s natural disposal system rather than simply blocking their activity.
C4 Therapeutics has concentrated its research and development efforts primarily on oncology, including programs aimed at genetically defined cancers and difficult-to-treat tumors.
Featured Articles
- Five stocks we like better than C4 Therapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
